¾î¸£½ÅÀÌ ÇູÇÑ ¼¼»ó
¼º»êµ¿ 2µî±Þ³²Àھ½Å¿ä¾çº¸È£»ç ±¸ÀÎ
¼¿ï | ¹«°ü | ~12/26
(D-325)
¿¡ÀÌÄ¡Ç÷¯½º¾çÁöº´¿ø
[¿¡ÀÌÄ¡Ç÷¯½º¾çÁöº´¿ø] ¿Ü·¡°£È£Á¶¹«»ç ä¿ë°ø°í
¼¿ï | ¹«°ü | ä¿ë½Ã
¼¾ÅÒºäÆ¼½ºÇǺΰú
ºäƼ½ºÇǺΰú °£È£Á¶¹«»ç ±¸ÀÎ
ºÎ»ê | ¹«°ü | ä¿ë½Ã
ÇѼֽŰæÁ¤½Å°úÀÇ¿ø
Á¢¼ö ¼±»ý´ÔÀ» ¸ðÁýÇÕ´Ï´Ù.
¼¿ï | ¹«°ü | ä¿ë½Ã
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ)
[±Û·Î¹ú Á¦¾à»ç] study start-up associate ä¿ë
¼¿ï | °æ·Â | ä¿ë½Ã
(ÀÇ)»ï¼ºÀÇ·áÀç´Ü
[°ºÏ»ï¼ºº´¿ø] ¿¹¹æ°ÇÁø¼¾ÅÍ ±â¾÷°ÇÁøÆÄÆ® °ÇÁøÁö¿øÁ÷ »ç¿ø ¸ðÁý
¼¿ï | ¹«°ü | ä¿ë½Ã
¿¬¼¼¹Ù¸¥Ä¡°ú
[ÁÖ5ÀÏÁ¦][¼÷¼ÒÁö¿ø][±³ÅëºñÁö¿ø][ÃÖ°í´ë¿ì] °³²±¸ °³Æ÷µ¿ ¿¬¼¼¹Ù¸¥Ä¡°ú¿¡¼ Á÷¿ø ä¿ëÇÕ´Ï´Ù.
¼¿ï | ¹«°ü | ~10/05
(D-243)
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ)
(sr.) pharmacovigilance specialist
¼¿ï | °æ·Â | ä¿ë½Ã
(ÀÇ)»ï¼ºÀÇ·áÀç´Ü
[°ºÏ»ï¼ºº´¿ø] ¼¿ïÁ¾ÇÕ°ÇÁø¼¾ÅÍ °ÇÁøÁö¿øÁ÷ »ç¿ø ¸ðÁý
¼¿ï | ¹«°ü | ä¿ë½Ã
ÁÖ½Äȸ»ç ÀÌÀ¯½É¸®¹ß´Þ¼¾ÅÍ
¾ð¾î, ÀÎÁöÇнÀ, ³îÀÌ, ¹Ì¼úÄ¡·á»ç ¼±»ý´ÔµéÀ» ¸ð½Ê´Ï´Ù.
ÀÎõ | °æ·Â | ä¿ë½Ã
¸¶µðưư ÅëÁõÀÇÇаú ÀçȰÀÇÇаú ÀÇ¿ø
¹æ»ç¼±»ç ½ÅÀÔ/°æ·Â ä¿ë
±¤ÁÖ | ¹«°ü | ~02/06
(D-2)
(ÀÇ)»ï¼ºÀÇ·áÀç´Ü
[°ºÏ»ï¼ºº´¿ø] ¼ö¿øÁ¾ÇÕ°ÇÁø¼¾ÅÍ °£È£Á¶¹«»ç ¸ðÁý
°æ±â | ¹«°ü | ä¿ë½Ã
(ÀÇ)»ï¼ºÀÇ·áÀç´Ü
[°ºÏ»ï¼ºº´¿ø] ¼ö¿øÁ¾ÇÕ°ÇÁø¼¾ÅÍ ÀÓ»óº´¸®»ç ¸ðÁý
°æ±â | ¹«°ü | ä¿ë½Ã
(ÁÖ)¿¡ÀÌÄ¡¾Ë±×·ì
»óÀå ¹ÙÀÌ¿Àȸ»ç - qa ´ã´çÀÚ
°æ±â | ¹«°ü | ~12/05
(D-304)
(ÁÖ)¿¡ÀÌÄ¡¾Ë±×·ì
»óÀå ¹ÙÀÌ¿À ȸ»ç »ç¾÷°³¹ß bd(business development)
°æ±â | ¹«°ü | ³»Àϸ¶°¨
(D-1)
(ÁÖ)¿¡ÀÌÄ¡¾Ë±×·ì
»óÀå¹ÙÀÌ¿Àȸ»ç Ä¡·áÁ¦°³¹ß neuroÆÀ (¹Ú»ç±Þ)
°æ±â | °æ·Â | ³»Àϸ¶°¨
(D-1)
(ÁÖ)¿¡ÀÌÄ¡¾Ë±×·ì
»óÀå¹ÙÀÌ¿ÀÁ¦¾à processÆÀ Á¤Á¦°øÁ¤°³¹ß
°æ±â | °æ·Â | ³»Àϸ¶°¨
(D-1)
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ)
[±Û·Î¹ú Á¦¾à»ç] sr. business intelligence data analyst ä¿ë
¼¿ï | °æ·Â | ~12/01
(D-300)
(ÀÇ)»ï¼ºÀÇ·áÀç´Ü
[°ºÏ»ï¼ºº´¿ø] ¼ö¿øÁ¾ÇÕ°ÇÁø¼¾ÅÍ ³»½Ã°æ½Ç ÀÌ¼Û»ç¿ø ¸ðÁý
°æ±â | ¹«°ü | ä¿ë½Ã
¹ÝÆ÷Á¾ÇÕ»çȸº¹Áö°ü
¹ÝÆ÷Á¾ÇÕ»çȸº¹Áö°ü ¹ß´Þ½É¸®»ó´ã»ç¾÷ ¾ð¾îÀçȰ»ç ¸ðÁý °ø°í
¼¿ï | ¹«°ü | ¿À´Ã¸¶°¨
(D-day)
¼¿ï °ºÏ±¸ ¼öÀ¯3µ¿ 177-23 (ÁÖ)ÄÄÅ×Å©ÄÁ¼³ÆÃ:À¯Á¾Çö
Á÷¾÷Á¤º¸Á¦°ø»ç¾÷½Å°í¹øÈ£ : ¼¿ïºÏºÎ Á¦ 2008-01È£
Copyright ¨Ï ¸ÞµðÄÃÀâ. All rights reserved.
¼¿ï °ºÏ±¸ ¼öÀ¯3µ¿ 177-23
(ÁÖ)ÄÄÅ×Å©ÄÁ¼³ÆÃ:À¯Á¾Çö
Á÷¾÷Á¤º¸Á¦°ø»ç¾÷½Å°í¹øÈ£
¼¿ïºÏºÎ Á¦ 2008-01È£
Copyright ¨Ï ¸ÞµðÄÃÀâ. All rights reserved.